Affiliation:
1. SİVAS CUMHURİYET ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, TEMEL ECZACILIK BİLİMLERİ BÖLÜMÜ
2. CUMHURİYET ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, TEMEL ECZACILIK BİLİMLERİ BÖLÜMÜ
Abstract
Covid-19, originating from Wuhan, China, is a worldwide health problem. Immune system abnormalities caused by covid-19 lead to infections, septic shock, and severe multi-organ dysfunction. The drugs used for treatment are palliative pharmacological alternatives and help manage symptoms or complications that occur during the course of the disease. Both carbonic anhydrases and cholinesterases can be target enzymes for drugs. The goal of this study is to determine how the drugs used in covid-19 affect patients being treated for Alzheimer's disease, myasthenia gravis, glaucoma, or epilepsy, and to determine if there are drug-drug interactions. In case of possible interactions, it is crucial for these patients to consider alternative treatments and to recheck the dosage of the drugs used. To this end, the effects of the drugs favipiravir and oseltamivir, which are used in the covid-19 clinic and whose relationship with these enzymes has not been previously studied, on the isoenzymes of carbonic anhydrase I- II and the enzyme acetylcholinesterase were studied in vitro. No inhibition or activation was observed on the enzyme acetylcholinesterase, while inhibition was observed for the isoenzyme carbonic anhydrase I - II.
Reference18 articles.
1. [1] Marcolino V. A., Pimentel T. C., Barao C. E., What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results, European Journal of Pharmacology, 887 (2020) 173467.
2. [2] Nechipurenko Y. D., Semyonov D. A., Lavrinenko I. A., Lagutkin, D. A., Generalov, E. A., Zaitceva, A. Y., Yegorov, Y. E., The Role of Acidosis in the Pathogenesis of Severe Forms of COVID-19. Biology, 10(9) (2021) 852.
3. [3] Akkemik E., Çalışır Ü., Çiçek B., İnsan karbonik anhidraz I, II izoenzim aktiviteleri üzerine bazı tiyocrown eterlerin etkisi, Balıkesir Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 19(2) (2017) 192-199.
4. [4] Thiry A., Dogne J. M., Supuran C. T., Masereel B., Carbonic anhydrase inhibitors as anticonvulsant agents, Current Topics in Medicinal Chemistry, 7(9) (2007): 855-864.
5. [5] Supuran, CT Karbonik anhidraz inhibitörleri: hipoksik tümörlerin tedavisi ve görüntülenmesi için deneysel ajanlar hakkında bir güncelleme, Araştırma İlaçları Hakkında Uzman Görüşü , 30(12) (2021) 1197-1208.